Viracta Therapeutics, Inc.
VIRX · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 73.3% |
| R&D Expenses | $33 | $26 | $24 | $13 |
| G&A Expenses | $17 | $24 | $15 | $5 |
| SG&A Expenses | $17 | $24 | $15 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$14 | -$0 |
| Operating Expenses | $51 | $51 | $26 | $19 |
| Operating Income | -$51 | -$51 | $63 | -$19 |
| % Margin | – | – | – | -15,679.2% |
| Other Income/Exp. Net | -$0 | $1 | -$75 | -$0 |
| Pre-Tax Income | -$51 | -$49 | -$115 | -$19 |
| Tax Expense | $0 | $1 | $88 | $0 |
| Net Income | -$51 | -$50 | -$203 | -$19 |
| % Margin | – | – | – | -15,999.2% |
| EPS | -1.32 | -1.32 | -6.37 | -0.52 |
| % Growth | 0% | 79.3% | -1,125% | – |
| EPS Diluted | -1.32 | -1.32 | -6.37 | -0.52 |
| Weighted Avg Shares Out | 39 | 38 | 32 | 37 |
| Weighted Avg Shares Out Dil | 39 | 38 | 32 | 37 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $1 | $0 | $0 |
| Interest Expense | $4 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$47 | -$48 | -$114 | -$19 |
| % Margin | – | – | – | -15,640.8% |